Equities

Wntresearch AB

Wntresearch AB

Actions
  • Price (SEK)0.1295
  • Today's Change0.010 / 7.92%
  • Shares traded3.18m
  • 1 Year change-50.17%
  • Beta0.5984
Data delayed at least 15 minutes, as of Apr 18 2024 09:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small molecules that can specifically interact with this process. The Company’s programs focus on the role of the Wnt-5a protein in the metastatic process. As of December 31, 2011, the Company had two projects, namely Foxy-5 and Box-5. Foxy-5 is a hexapeptide mimicking the effects of WNT-5a. Box-5 is a peptide antagonizing the effects of Wnt-5a. As of March 31, 2012, the Company’s largest shareholder was Forskarpatent I Syd AB, which held 26.55% shares.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-32.47m
  • Incorporated2007
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abera Bioscience AB0.00-16.72m79.53m----13.25-----1.24-1.240.000.3910.00-------115.63-79.43-149.06-96.11--------------------13.73------
Bioextrax AB publ2.06m-21.51m80.80m----3.37--39.28-0.8026-0.80260.07690.69680.0681--124.67---71.18-86.39-82.24-110.8434.95---1,045.55-2,119.90--------420.5124.40-15.21--56.86--
Biosergen AB0.00-27.04m83.63m3.00--10.78-----0.4007-0.40070.000.04180.00----0.00-131.31---217.09----------------------32.25------
AroCell AB (publ)43.04m-59.30m86.39m----0.5279--2.01-0.2574-0.25740.18680.71040.20956.686.52---28.86-29.25-30.70-31.37-4.38-9.85-137.78-231.195.25--0.00--16.37122.92-0.5494------
Ziccum AB3.75m-21.41m93.27m----9.82--24.89-1.54-1.540.27030.61910.1553--2.01---88.74-68.51-109.73-76.47-----571.44-2,598.03----0.0908----75.2025.62------
Sprint Bioscience AB50.49m-441.00k94.26m28.00--3.3913,465.301.87-0.0064-0.00640.72320.39781.01--7.581,803,036.00-0.8838-71.22-1.58-113.7182.7762.75-0.8735-110.22----0.00--60,725.3022.9999.27---26.02--
Annexin Pharmaceuticals AB (publ)0.00-44.05m94.96m4.00--5.05-----0.189-0.1890.000.05430.00----0.00-138.88-125.42-179.93-151.33------------0.00-------8.17------
NextCell Pharma AB12.22m-40.69m97.64m----1.48--7.99-1.18-1.180.35551.920.12414.666.80---41.28-34.92-45.63-37.066.61-68.21-332.90-538.604.97--0.00--80.9672.85-15.21------
Scandion Oncology A/S0.00-61.33m98.80m4.00--2.03-----1.52-1.520.001.200.00----0.00-63.25-45.09-76.67-52.65------------0.0158------48.89------
Bactiquant A/S19.25m-20.51m98.91m----4.39--5.14-0.6358-0.63580.59710.61330.50553.672.83---53.83-41.26-62.59-47.16-6.1412.89-106.51-71.775.43-8.540.0431---0.689--7.62------
Wntresearch AB0.00-32.47m103.93m2.00--0.6543-----0.1108-0.11080.000.18340.00-------134.87-100.71-166.68-123.59---------------------5.65------
Dextech Medical AB0.00-4.57m104.45m1.00--3.23-----0.2473-0.24730.001.750.00-------13.04-28.96-13.21-29.94------------0.00------12.89--0.412--
Toleranzia AB0.00-7.46m104.45m----0.6804-----0.0597-0.05970.000.7790.00-------5.21-7.45-5.43-7.78------------0.0055------11.79--63.90--
Isofol Medical AB (publ)721.00k-37.07m104.99m3.00--0.8646--145.61-0.2164-0.21640.00440.75180.0041--0.0728240,333.30-21.15-66.73-26.32-88.27-4,773.23---5,141.61-1,023.62---------94.37--76.80------
Opticept Technologies AB9.15m-80.36m119.44m29.00--0.3247--13.06-2.51-2.510.28448.720.0213-0.06382.37315,344.80-18.69-41.76-21.18-46.20125.8862.65-879.64-882.410.6216-14.160.0566---12.9049.1719.80--45.22--
StenoCare A/S5.88m-27.49m123.70m9.00--3.02--21.04-1.29-1.290.2711.420.0967--1.25417,535.60-45.21-28.15-63.19-35.47-----467.55-371.061.30-5.540.2727---16.30---7.77------
Data as of Apr 18 2024. Currency figures normalised to Wntresearch AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.